HDAC Inhibition Blunts Ischemia/Reperfusion Injury by Inducing Cardiomyocyte Autophagy

BACKGROUND: Reperfusion accounts for a substantial fraction of the myocardial injury occurring with ischemic heart disease. Yet, no standard therapies are available targeting reperfusion injury. Here, we tested the hypothesis that SAHA, a histone deacetylase (HDAC) inhibitor FDA-approved for cancer...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Xie, Min, Kong, Yongli, Tan, Wei, May, Herman, Battiprolu, Pavan K., Pedrozo, Zully, Wang, Zhao, Morales, Cyndi, Luo, Xiang, Cho, Geoffrey, Jiang, Nan, Jessen, Michael E., Warner, John J., Lavandero, Sergio, Gillette, Thomas G., Turer, Aslan T., Hill, Joseph A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3984913/
https://ncbi.nlm.nih.gov/pubmed/24396039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.113.002416
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak